Subscribe Now
Forgot Password?

Weekly News, Analysis, and Commentary

Company News Feature

Kiva System / Courtesy: Benvenue Medical, Inc.

Kiva Meets Clinical Trial Endpoint

Walter Eisner • Wed, May 22nd, 2013

Print this article

Benvenue Medical, Inc. just completed its 12-month follow-up on patients in the company's KAST clinical trial.

The results? The company announced on May 21, 2013 that the study ended early because the trial met the pre-determined stopping rules (non-inferiority).

Next Stop: FDA

The KAST (Kiva System as a Vertebral Augmentation Treatment – A Safety and Effectiveness Trial) clinical trial was conducted to support a 510(k) application for market clearance from the FDA, which the company expects to submit in the third quarter of 2013.

Sean Tutton, M.D., FSIR, co-principal investigator of the study and professor of radiology and surgery at the Medical College of Wisconsin in Milwaukee said, “We anticipate the results will be important to guiding treatment recommendations for VCFs.” Benvenue's CEO, Robert Weigle, said the company is having a "positive collaboration with the FDA on our progress. KAST met the pre-determined stopping rules for enrollment completion and also enrolled ahead of schedule. Lastly, 98% of eligible patients were followed out to one year."

Kiva vs. Kyphoplasty

The trial evaluated the Kiva Vertebral Compression Fracture (VCF) Treatment System in one of the largest, according to the company, randomized studies to date versus the current standard of care in the treatment of VCFs—balloon kyphoplasty. The primary endpoint was non-inferiority on a composite of pain, function, and safety at one year of follow-up on patients treated in the study. Three hundred patients were enrolled at 21 medical centers in the U.S., Canada, Belgium, France and Germany.

The study was designed to evaluate superiority on key secondary endpoints including PMMA (polymethyl methacrylate) cement volume, extravasation rate, and height restoration as well as other endpoints.

Kiva System

According to the company, the Kiva system features a proprietary flexible implant made from PEEK-OPTIMA, a biocompatible polymer. The implant is designed to function as a mechanical support structure and a reservoir to direct and contain the flow of bone cement.

The implant is delivered percutaneously in a continuous loop into the vertebral body through a small diameter, single incision. The amount of the implant delivered can be physician-customized during the procedure to adjust to various fracture types. Delivered over a removable guidewire, the implant is designed to provide stabilization and structural support to the vertebral body and to directionally control and contain bone cement.

A separate European randomized trial of Kiva and balloon vertebral augmentation was recently published in the February edition of Spine (2013;38:292-299). This Level I data, says the company, demonstrated Kiva’s superiority over balloons in key areas:

  • Significant restoration of the Gardner angle in patients treated with Kiva ( p=0.002) whereas  balloon kyphoplasty did not meet significance (p=0.067)
  • Lower cement extravasation rates (3% for Kiva and 9.8% for balloon kyphoplasty, p<0.05)
  • Lower cement volume (1.8 mL for Kiva and 2.8 mL for balloon kyphoplasty, p <0.001)

The National Osteoporosis Foundation estimates that there are 700, 000 osteoporosis-related vertebral compression fractures annually in the U.S. alone, yet 200, 000 kyphoplasty procedures are done globally.

Send to a Friend

The article link will be sent to the email address you provide

Your Name (required)

Your Email (required)

Friend's Email (required)


Leave a Reply


Email Address (will not be published)